Abstract 165P
Background
Sorafenib has been the standard-of-care in advanced hepatocellular carcinoma (HCC). Prognostic factors such as BCLC stage and macroscopic vascular invasion (MVI), together with predictive factors of response such as neutrophil-lymphocyte ratio (NLR), cirrhosis etiology and extrahepatic spread (EHS) were found to be associated to survival outcomes. Nevertheless, these factors need to be fully validated. We intend to explore and identify prognostic factors for overall survival (OS) in a European population sample treated with sorafenib.
Methods
Multicentre retrospective evaluation of patients’ (pts) charts of HCC pts with ECOG performance status (PS) ≤2 treated with sorafenib between 2008 and 2019 in two Portuguese centres. Alfa- fetoprotein (AFP) < 200 ng/mL, EHS, Model for End-Stage Liver Disease-Na (MELD-Na) < 17, cutaneous toxicity, NLR < 2.3, MVI and previous locoregional treatment (LRT) were considered for stratification. Each factor was analyzed by Kaplan-Meier method for OS estimation and a multivariate Cox regression was performed.
Results
Eighty-six pts were analyzed, 15% female and with a median age (med) of 65.5 years [36-83]. Considering underlying cause, 45% pts had alcohol-related liver disease, 23% hepatitis C virus, 14% hepatitis B virus and 5% non-alcoholic steatosis hepatitis. Median OS was 8.5 months (m). Kaplan-Meier analysis of OS proved to be statistical significant in the following factors: AFP < 200 ng/mL med OS 12.5 m and ≥ 200 ng/mL 5.4 m (p < 0.0001); MELD-Na < 17 med OS 10.4 m and ≥ 17 4.8 m (p=0.015); absence of EHS med OS 10.0 m and presence of EHS med OS 7.3 m (p=0.028); previous LRT med OS 11.2 m and no LRT med OS 6.6 m (p=0.005). Multivariate Cox analysis identified extra-hepatic involvement (HR 1.002, p=0.041) and no previous LRT (HR 1.871, p=0.009) as risk factors.
Conclusions
HCC pts represent a heterogeneous population with many factors that potentially affect prognosis, such as geographic etiology difference in hepatic cirrhosis. In our sample, analysis of single-variable subgroups estimated greater OS in pts with AFP < 200 ng/mL, MELD-Na < 17, absence of EHS and previous LRT. The multivariate regression showed EHS and no previous LRT are independent factors for worse prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session